CR20240300A - Derivados espirocíclicos de piperidinilo como inhibidores del factor b del complemento y usos de los mismos. - Google Patents
Derivados espirocíclicos de piperidinilo como inhibidores del factor b del complemento y usos de los mismos.Info
- Publication number
- CR20240300A CR20240300A CR20240300A CR20240300A CR20240300A CR 20240300 A CR20240300 A CR 20240300A CR 20240300 A CR20240300 A CR 20240300A CR 20240300 A CR20240300 A CR 20240300A CR 20240300 A CR20240300 A CR 20240300A
- Authority
- CR
- Costa Rica
- Prior art keywords
- spirocyclic
- inhibitors
- complement factor
- piperidinyl derivatives
- piperidinyl
- Prior art date
Links
- 102000003712 Complement factor B Human genes 0.000 title abstract 2
- 108090000056 Complement factor B Proteins 0.000 title abstract 2
- -1 PIPERIDINYL Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263302246P | 2022-01-24 | 2022-01-24 | |
| PCT/IB2023/050504 WO2023139534A1 (en) | 2022-01-24 | 2023-01-20 | Spirocyclic piperidinyl derivatives as complement factor b inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20240300A true CR20240300A (es) | 2024-08-23 |
Family
ID=85150566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20240300A CR20240300A (es) | 2022-01-24 | 2023-01-20 | Derivados espirocíclicos de piperidinilo como inhibidores del factor b del complemento y usos de los mismos. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20250115572A1 (https=) |
| EP (1) | EP4469157A1 (https=) |
| JP (1) | JP2025504859A (https=) |
| KR (1) | KR20240138095A (https=) |
| CN (1) | CN118696035A (https=) |
| AU (1) | AU2023209631A1 (https=) |
| CA (1) | CA3247772A1 (https=) |
| CL (1) | CL2024002205A1 (https=) |
| CO (1) | CO2024009660A2 (https=) |
| CR (1) | CR20240300A (https=) |
| DO (1) | DOP2024000142A (https=) |
| IL (1) | IL314186A (https=) |
| JO (1) | JOP20240165A1 (https=) |
| MX (1) | MX2024009062A (https=) |
| PE (1) | PE20242005A1 (https=) |
| WO (1) | WO2023139534A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202334121A (zh) * | 2021-10-27 | 2023-09-01 | 美商翰森生物有限責任公司 | 哌啶基吲哚衍生物、其製備方法及醫藥用途 |
| TW202423426A (zh) * | 2022-08-31 | 2024-06-16 | 美商奇努克醫療股份有限公司 | 經取代之吲哚化合物及其使用方法 |
| IL320661A (en) * | 2022-11-14 | 2025-07-01 | Novartis Pharma Ag | Solid forms of complement factor B inhibitors |
| TW202506657A (zh) * | 2023-04-27 | 2025-02-16 | 大陸商上海翰森生物醫藥科技有限公司 | 一種哌啶基吲哚化合物的鹽及其製備方法 |
| CN121889385A (zh) | 2023-07-04 | 2026-04-17 | 希塔拉生物有限公司 | 作为因子b抑制剂的2-(1h-吲哚-4-基)甲基)2h-吲唑衍生物 |
| IL325760A (en) | 2023-07-04 | 2026-03-01 | Sitala Bio Ltd | History of 2-(1H-indol-4-yl)methyl)-isoindoline as factor B inhibitors |
| WO2025008516A2 (en) | 2023-07-06 | 2025-01-09 | Sitala Bio Ltd | Novel compounds |
| WO2025008517A1 (en) | 2023-07-06 | 2025-01-09 | Sitala Bio Ltd | Indole derivatives with factor b inhibitory activity |
| AU2024324780A1 (en) * | 2023-08-16 | 2026-02-05 | Inflarx Gmbh | Fused piperidinyl bicyclic and related compounds for use in the treatment of diseases |
| WO2025172535A1 (en) | 2024-02-15 | 2025-08-21 | Sitala Bio Ltd | Indole and benzimidazole compounds as factor b inhibitors |
| TW202543599A (zh) * | 2024-03-08 | 2025-11-16 | 大陸商江蘇豪森藥業集團有限公司 | 一種多元螺環化合物的晶型、其製備方法和醫藥用途 |
| WO2025256600A1 (zh) * | 2024-06-12 | 2025-12-18 | 润尔眼科药物（广州）有限公司 | 一种杂环化合物及其用途 |
| WO2026002007A1 (zh) * | 2024-06-25 | 2026-01-02 | 珠海联邦制药股份有限公司 | 补体因子b抑制剂及其药物组合物和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| JO3265B1 (ar) | 2008-12-09 | 2018-09-16 | Novartis Ag | مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض |
| JO3425B1 (ar) | 2013-07-15 | 2019-10-20 | Novartis Ag | مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b |
| RS66635B1 (sr) * | 2017-08-31 | 2025-04-30 | Novartis Ag | Derivati piperidinil-indola za upotrebu u lečenju c3 glomerulopatije |
| KR20230049115A (ko) * | 2020-08-07 | 2023-04-12 | 상하이 메이유에 바이오테크 디벨롭먼트 컴퍼니 리미티드 | 보체 인자 b 억제제 및 이의 약학적 조성물, 제조 방법 및 용도 |
| CN120081822A (zh) * | 2021-06-03 | 2025-06-03 | 诺瓦提斯药物公司 | 经取代的吲哚化合物及其使用方法 |
| EP4389742A4 (en) * | 2021-08-18 | 2026-01-14 | Xizang Haisco Pharmaceutical Co Ltd | HETEROAROMATIC CYCLE DERIVATIVE CONTAINING BENZO NITROGEN AND ITS USE IN MEDICINE |
| TW202334121A (zh) * | 2021-10-27 | 2023-09-01 | 美商翰森生物有限責任公司 | 哌啶基吲哚衍生物、其製備方法及醫藥用途 |
-
2023
- 2023-01-20 CA CA3247772A patent/CA3247772A1/en active Pending
- 2023-01-20 CR CR20240300A patent/CR20240300A/es unknown
- 2023-01-20 JP JP2024543097A patent/JP2025504859A/ja active Pending
- 2023-01-20 CN CN202380019453.6A patent/CN118696035A/zh active Pending
- 2023-01-20 PE PE2024001666A patent/PE20242005A1/es unknown
- 2023-01-20 AU AU2023209631A patent/AU2023209631A1/en active Pending
- 2023-01-20 EP EP23702675.2A patent/EP4469157A1/en active Pending
- 2023-01-20 WO PCT/IB2023/050504 patent/WO2023139534A1/en not_active Ceased
- 2023-01-20 IL IL314186A patent/IL314186A/en unknown
- 2023-01-20 MX MX2024009062A patent/MX2024009062A/es unknown
- 2023-01-20 US US18/729,949 patent/US20250115572A1/en active Pending
- 2023-01-20 KR KR1020247027601A patent/KR20240138095A/ko active Pending
-
2024
- 2024-07-22 CO CONC2024/0009660A patent/CO2024009660A2/es unknown
- 2024-07-22 CL CL2024002205A patent/CL2024002205A1/es unknown
- 2024-07-22 DO DO2024000142A patent/DOP2024000142A/es unknown
- 2024-07-24 JO JOJO/P/2024/0165A patent/JOP20240165A1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025504859A (ja) | 2025-02-19 |
| WO2023139534A1 (en) | 2023-07-27 |
| KR20240138095A (ko) | 2024-09-20 |
| IL314186A (en) | 2024-09-01 |
| MX2024009062A (es) | 2024-07-29 |
| CO2024009660A2 (es) | 2024-07-29 |
| AU2023209631A1 (en) | 2024-07-25 |
| CL2024002205A1 (es) | 2025-01-10 |
| DOP2024000142A (es) | 2024-08-30 |
| US20250115572A1 (en) | 2025-04-10 |
| CA3247772A1 (en) | 2023-07-27 |
| PE20242005A1 (es) | 2024-10-03 |
| CN118696035A (zh) | 2024-09-24 |
| JOP20240165A1 (ar) | 2024-07-24 |
| EP4469157A1 (en) | 2024-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2024009660A2 (es) | Derivados espirocíclicos de piperidinilo como inhibidores del factor b del complemento y usos de los mismos | |
| UY40204A (es) | Inhibidores del Factor B del Complemento y Usos de los mismos | |
| CO2022018811A2 (es) | Inhibidores de la proteína kras g12c y usos de estos | |
| CO2022008092A2 (es) | N4-hidroxicitidina y derivados y usos antivirales relacionados con los mismos | |
| MX2024004921A (es) | Derivados de piperidinilindol, metodos de preparacion y usos medicinales de estos. | |
| AR132802A1 (es) | 2-amino-3-cianotiofenos con anillos espirocíclicos y derivados para el tratamiento del cáncer | |
| MX390535B (es) | Compuestos de amino-triazolopiridina y su uso en el trataniento del cancer. | |
| AR123685A1 (es) | Antagonistas del mrgx2 | |
| MX2020006438A (es) | Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1. | |
| CL2025000629A1 (es) | Inhibidores de parp1 de azetidina y pirrolidina y usos de estos | |
| AR133953A1 (es) | Inhibidores del factor b del complemento y usos de los mismos | |
| SV2018005750A (es) | Derivados de compuestos de indol sustituidos como inhibidores de la replicacion virica del dengue | |
| CL2021000329A1 (es) | Compuestos útiles en terapia del vih | |
| CL2017001984A1 (es) | Compuestos tricíclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr).(solicitud divisional 3355-2014) | |
| ECSP18073293A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| UY29458A1 (es) | Heterociclos sustituidos y usos de los mismos | |
| DOP2010000064A (es) | 2-anilinopurin 8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos | |
| MX2025010920A (es) | Compuestos quimicos | |
| CO2021012579A2 (es) | Compuestos útiles en la terapia del vih | |
| MX2020014156A (es) | Oxadiazoles como agonistas de los receptores muscarinicos m1 y/o m4. | |
| CL2021001388A1 (es) | Compuestos útiles en la terapia para el vih | |
| CL2023000670A1 (es) | Compuestos heterocíclicos como inhibidores del bromodominio cbp/ep300 | |
| NI201600176A (es) | Compuestos de 1, 3, 4 - tiadiazol y uso de los mismos para el tratamiento del cáncer. | |
| MX2017016370A (es) | Derivados de 4-bencil y 4-benzoil piperidina sustituidos. | |
| AR132698A1 (es) | DERIVADOS ESPIRO COMO INHIBIDORES DE LA HELICASA TIPO RecQ DEL SÍNDROME DE WERNER (WRN) |